Skip to main content
SpringerLink
Log in

The unregulated commercialization of stem cell treatments: a global perspective

  • Review
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Research into the biological properties and clinical potential of stem cells has spurred strong public investment, industry development, media coverage, and patient interest in recent years. To date, however, few clinical applications of demonstrated safety and efficacy have been developed with the exception of uses of hematopoietic stem cells in the treatment of diseases of the blood and immune systems. This lack of an evidence basis notwithstanding, hundreds of companies and private clinics around the world now sell putative stem cell treatments for an enormously broad range of medical and quality-of-life conditions. This represents a major challenge for legitimate scientists working in the field, for authorities seeking to protect their constituencies, and for patients and consumers targeted by such companies’ marketing strategies. In this review, I provide an overview of the global industry in pseudomedical stem cell treatments, with an investigation of claims in a single disease area (amyotrophic lateral sclerosis), and make recommendations for the introduction and enforcement of appropriate regulatory responses to this problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM). Osiris Therapeutics. NCT 00690066

  2. Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury. Stem Cells Inc. NCT01321333

  3. Pilot Investigation of Stem Cells in Stroke (PISCES). ReNeuron Ltd. NCT01151124

  4. Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS. The Cleveland Clinic. NCT00813969

  5. XCell-Center. Köln/Düsseldorf, Germany. http://www.xcell-center. com/

  6. Nova Cells Institute. Mexico. http://www.novacellsinstitute.com/

  7. Wu Stem Cells Medical Center. Beijing, China. http://www. unistemcells.com/

  8. Rejuvenare. Dominican Republic. http://www.rejuvenare.com/

  9. EmCell. Kiev, Ukraine. http://www.emcell.com/en/list_of_diseases/aids.htm

  10. Stem Cell Therapies. USA/Mexico. http://www.stemcelltherapies. org/umresearch/downs.html

  11. CellPort Clinic. Yokohama, Japan. http://www.cellport.jp/english/

  12. RecoverUp Stem cell Hair Regeneration. Scotland, UK. http://www.recoverup.com/

  13. Repair Stem Cell Institute. Bangkok, Thailand. http://www.repairstemcells.org/Treatment/Diseases-Treated.aspx

  14. WIPO Patent. Compositions Comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation. WO 2007141657 20071213

  15. Blakely R. Stem cell experts sceptical of Dr Geeta Shroff’s miracle cure claims. The Times. London, UK. 7 Nov 2009. Accessed at: http://www.timesonline.co.uk/tol/life_and_style/health/features/article6906985.ece

  16. Medra Inc. Dominican Republic. http://www.medra.com/

  17. Stem Cells for Hope. Mt. Sinai, NY, USA. http://www.stemcellsforhope. com/

  18. Asian Stem Cell Regeneration Institute. Manila, The Philippines. http://www.stem-cell-regeneration.com/

  19. Sipp D. Stem cell stratagems in alternative medicine. Regen Med 2011; 6(3): 407–414

    Article  PubMed  Google Scholar 

  20. Jandial R, Snyder EY. A safer stem cell: on guard against cancer. Nat Med 2009; 15(9): 999–1001

    Article  PubMed  CAS  Google Scholar 

  21. Ward V. Stem cell doctor Robert Trossel struck off medical register. The Daily Telegraph. London, UK. 30 Sep 2010. Accessed at: http://www.telegraph.co.uk/health/healthnews/8033130/Stem-cell-doctor-Robert-Trossel-struck-off-medical-register.html

  22. Kuznetsov V. Some Background on the Russian Stem Cell Market. Russia Blog. 25 June 2007. Accessed at: http://www.russiablog.org/2007/06/investing_in_russia_background.php

  23. Cyranoski D. Stem-cell therapy faces more scrutiny in China. Nature 2009; 459(7244): 146–147

    Article  PubMed  Google Scholar 

  24. Stem Cell Rejuvenation Center. Phoenix, AZ, USA. http://www. stem-cell-center.com/

  25. Clinic O. Tokyo, Japan. http://www.odaclinic.net/

  26. Biotechnology B. Shenzhen, China. http://www.beikebiotech.com/

  27. Chaitanya Stem Cell Center. Pune, India. http://chaitanyastemcell. com/

  28. American Stem Cell & Anti-Aging Center. Quito, Ecuador. http://www.ascaac.com/

  29. Stem Cell Institute. Panama City, Panama. http://www.cellmedicine. com/

  30. Regenobody. Sosua, Dominican Republic. http://www.regenobody. com/

  31. Tissü. Seychelles. http://www.tissustemcell.com/

  32. Altaco XXI. Astana, Kazakhstan. http://www.stem-cell.kz/

  33. Amni Health Services. Dubai, UAE. http://amnihealthservices.com/

  34. China Stem Cell News. http://www.stemcellschina.com

  35. Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 2008; 3(6): 591–594

    Article  PubMed  CAS  Google Scholar 

  36. Zarzeczny A, Rachul C, Nisbet M, Caulfield T. Stem cell clinics in the news. Nat Biotechnol 2010; 28(12): 1243–1246

    Article  PubMed  CAS  Google Scholar 

  37. Ryan KA, Sanders AN, Wang DD, Levine AD. Tracking the rise of stem cell tourism. Regen Med 2010; 5(1): 27–33

    Article  PubMed  CAS  Google Scholar 

  38. Sipp D. The rocky road to regulation. Nature Rep Stem Cells 2009. http://www.nature.com/stemcells/2009/0909/090923/full/stemcells. 2009.125.html

  39. Regenberg AC, Hutchinson LA, Schanker B, Mathews DJH. Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells 2009; 27(9): 2312–2319

    Article  PubMed  Google Scholar 

  40. Kiatpongsan S, Sipp D. Medicine. Monitoring and regulating offshore stem cell clinics. Science 2009; 323(5921): 1564–1565

    Article  PubMed  CAS  Google Scholar 

  41. Japanese Society for Regenerative Medicine. http://www.jsrm.jp/news/110303.html (Japanese language announcement)

  42. Gunter KC, Caplan AL, Mason C, Salzman R, Janssen WE, Nichols K, Bouzas LF, Lanza F, Levine BL, Rasko JE, Shimosaka A, Horwitz E. Cell therapy medical tourism: time for action. Cytotherapy 2010; 12(8): 965–968

    Article  PubMed  Google Scholar 

  43. Taylor PL, Barker RA, Blume KG, Cattaneo E, Colman A, Deng H, Edgar H, Fox IJ, Gerstle C, Goldstein LS, High KA, Lyall A, Parkman R, Pitossi FJ, Prentice ED, Rooke HM, Sipp DA, Srivastava A, Stayn S, Steinberg GK, Wagers AJ, Weissman IL. Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell 2010; 7(1): 43–49

    Article  PubMed  CAS  Google Scholar 

  44. A closer look at stem cells. http://www.closerlookatstemcells.org/

  45. Carroll R. Costa Rican health ministry bans experimental stem cell treatment. Guardian. London, UK. 7 June (2010) Accessed at: www.guardian.co.uk/world/2010/jun/07/costa-rica-stem-cell-treatment

  46. Sheldon T. The Netherlands bans private stem cell therapy. BMJ 2007; 334(7583): 12

    Article  PubMed  Google Scholar 

  47. Than K. Hungary detains 4 over illegal stem cell treatment. Reuters 29 Jul 2009. Accessed at: http://www.reuters.com/article/2009/07/29/idUSLT392157

  48. Sirisunthon S, Sarnsamak P. Medical Council issues new decree to control stem cell research. The Nation. Bangkok, Thailand. 29 May 2009. Accessed at: http://www.nationmultimedia.com/2009/05/26/national/national_30103591.php

  49. Cyranoski D. Stem-cell therapy faces more scrutiny in China. Nature 2009; 459(7244): 146–147

    Article  PubMed  Google Scholar 

  50. Heyer M. Do therapies based on the application of the body’s own adult stem cells need authorization or approval? An evaluation. Accessed at: http://www.stemcells.nrw.de/en/lead-up-to-zelluxnetthe-school-portal-for-stem-cell-research/beduerfen-therapien-aufder-grundlage-der-verabreichung-koerpereigener-adulter-stammzellen-einer-zulassung-oder-genehmigung-eine-einschaetzung.html

  51. Kawakami M, Sipp D, Kato K. Regulatory impacts on stem cell research in Japan. Cell Stem Cell 2010; 6(5): 415–418

    Article  PubMed  CAS  Google Scholar 

  52. Progencell. San Diego, CA, USA. http://www.progencell.com/

  53. Regenocyte. Bonita Springs, FL, USA. www.regenocyte.com

  54. Koustas WT. Rdegenerative Sciences faced with FDA injunction. FDA Law Blog 21 Aug 2010. http://www.fdalawblog.net/fda_law_-blog_hyman_phelps/2010/08/regenerative-sciences-faced-with-fdainjunction. html

  55. ICMS. Open Letter to Stem Cell Clinics. 2 Aug 2010. Accessed at: http://www.cellmedicinesociety.org/attachments/233_Open% 20Letter%20To%20Stem%20Cell%20Clinics%20v2.pdf

  56. Koustas WT. Regenerative Sciences, Inc. attempts to avoid FDA action. FDA Law Blog 27 Jun 2010. Accessed at: http://www. fdalawblog.net/fda_law_blog_hyman_phelps/2010/06/regenerative-sciences-inc-attempts-to-avoid-fda-action.html

  57. Integra Medical Center. Nuevo Progreso, Mexico. http://www. dromargonzalez.com/

  58. Healing the Eye. Cave Creek, AZ, USA. http://www.healingtheeye. com/Articles/Stem_cell_ARMD.html

  59. Stem Cell Natural Therapy. Chiang Mai, Thailand. http://stemcellnaturaltherapy. com/

  60. Kim D. CO, USA. http://www.naturalmedicinedr.com/

  61. Dedeepiya V, John S, Abraham S. The gravity of regenerative medicine; Physics, chemistry & Biology behind it. J of Stem Cells and Regen Med 2008. 6(1) 22–23. Accessed at: http://www. pubstemcell.com/monthly/uploads/004010700011.pdf

    Google Scholar 

  62. Best Stem Cell Therapies. India. http://www.beststemcelltherapies. com/

  63. BioPathics. Palm Beach Gardens, FL, USA. http://www.hereisyoursite. us/www.biopathics.com/livecelltissueextracts[1].htm

  64. Unproven methods of cancer management: Fresh cell therapy. CA — A Cancer Journal for Clinicians. 31 Dec 2008. Accessed at: http://onlinelibrary.wiley.com/doi/10.3322/canjclin.41.2.126/pdf

  65. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–1700

    Article  PubMed  CAS  Google Scholar 

  66. Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, Halperin RF, Stamper C, Jensen KR, Letizia D, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, Mozaffar T, Jackson CE, Bosch P, McVey A, Dick A, Barohn R, Lomen-Hoerth C, Rosenfeld J, O’connor DT, Zhang K, Crook R, Ryberg H, Hutton M, Katz J, Simpson EP, Mitsumoto H, Bowser R, Miller RG, Appel SH, Stephan DA. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007; 357(8): 775–788

    Article  PubMed  CAS  Google Scholar 

  67. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; (1): CD001447

  68. Emory ALS. Center. Atlanta, GA, USA. http://www.neurology. emory.edu/ALS/Stem%20Cell.html

  69. Vlieland ND, Haberland N, Sipos L, Tamaschke UK, Happich D, Kleinbloesem CH. Autologous Stem Cell Transplantation in patients with Amyotrophic Lateral Sclerosis. (poster presentation). Accessed at: http://www.xcell-center.com/media/150697/poster_-als_a3.pdf

  70. ALSUntangled Group. ALSUntangled update 4: investigating the XCell-Center. Amyotroph Lateral Scler 2010; 11(3): 337–338

    Article  Google Scholar 

  71. Biotechnology B. Patient Information Guide Summer 2010. Accessed at: http://beikebiotech.com/information/Beike-Information-Guide.pdf

  72. Biotechnology B. Clinical Studies webpage. http://www.beikebiotech. com/index.php?option = com_content&view = article&id = 422&Itemid = 100008

  73. US Code of Federal Regulations Title 21, Part 1271. Accessed at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart = 1271

  74. Patra PK, Sleeboom-Faulkner M. Bionetworking: Between Guidelines and Practice in Stem Cell Therapy Enterprise in India. (2010) 7:2 SCRIPTed 295, http://www.law.ed.ac.uk/ahrc/script-ed/vol7-2/patra.asp

  75. Cyranoski D. Korean deaths spark inquiry. Nature 2010; 468(7323): 485

    Article  PubMed  CAS  Google Scholar 

  76. Sipp D. Stem cell research in Asia: a critical view. J Cell Biochem 2009; 107(5): 853–856

    Article  PubMed  CAS  Google Scholar 

  77. VesCell press release. Stem cell plant to bring treatment to thousands. 13 Oct 2005. Accessed at: http://vescell.com/stem-cellnews/34

  78. ISSCR. Patient handbook on stem cell therapies. http://www.isscr.org/clinical_trans/pdfs/ISSCRPatientHandbook.pdf

  79. International Campaignfor Cures of Spinal Cord Inury Paralysis (ICCP). Experimental treatments for spinal cord injury: What you should know. Accessed at: http://icord.org/wp-content/uploads/2009/07/Experimental_treatment_for_SCI-summary.pdf

  80. UK Multiple Sclerosis Society. Stem cell therapies in MS. http://www.mssociety.org.uk/downloads/International_MS_Society_Public_Information_Booklet_on_Stem_Cells.c1a8e3bd.pdf

  81. Worldwide ALS. A Patient’s guide through the maze of stem cell transplantation. http://www.alsworldwide.org/documents/APatient-PathThroughtheMaze.pdf

  82. UK Multiple Sclerosis Society. MS Society warning over ’stem cell’ treatments. 2 Dec 2008. http://www.mssociety.org.uk/news_events/news/press_releases/ibs_stem_cells.html

  83. Zarembo A. A desperate injection of stem cels and hope. Los Angeles Times 20 Feb 2005. Accessed at: http://www.latimes.com/features/health/medicine/la-sci-stemcells20feb20,1,4516556.story

  84. Panorama BBC. Stem cells and miracles. 18 May 2009. Summary at: http://news.bbc.co.uk/panorama/hi/front_page/newsid_8040000/8040872.stm

Download references

Author information

Authors and Affiliations

  1. Research Unit for Science Policy and Ethics Studies, RIKEN Center for Developmental Biology, 2-2-3 Minatojima Minamimachi, Chuo-ku, Kobe, 650-0047, Japan

    Douglas Sipp

Authors
  1. Douglas Sipp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Sipp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sipp, D. The unregulated commercialization of stem cell treatments: a global perspective. Front. Med. 5, 348–355 (2011). https://doi.org/10.1007/s11684-011-0150-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-011-0150-x

Keywords

Search

Navigation